Keyword Analysis & Research: dostarlimab

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
dostarlimab	1.89	0.7	529	83	11

Keyword	CPC	PCC	Volume	Score
dostarlimab	1.21	0.9	4479	37
dostarlimab fda approval	1.57	0.9	808	75
dostarlimab-gxly	0.12	0.9	7363	17
dostarlimab rectal cancer	1.52	0.8	8714	78
dostarlimab package insert	1.6	0.1	642	71
dostarlimab gsk	0.01	1	7459	10
dostarlimab price	0.4	0.4	7086	51
dostarlimab smpc	0.39	0.8	3569	58
dostarlimab endometrial cancer	0.89	0.7	8260	31
dostarlimab jemperli	1.27	0.7	3402	76
dostarlimab spc	1.27	0.7	1953	65
dostarlimab ema	1.64	0.6	7871	18
dostarlimab side effects	0.47	0.9	4580	34
dostarlimab vs pembrolizumab	0.96	1	9309	48
dostarlimab moa	1.05	1	1568	75
dostarlimab drug	0.62	0.3	3000	38
dostarlimab uspi	0.41	0.1	1256	75
dostarlimab fda	1.29	0.3	3359	94
dostarlimab mechanism of action	1.81	1	9154	69
dostarlimab immunotherapy	0.23	0.3	7941	52
dostarlimab fda label	0.5	0.3	1920	78
dostarlimab fachinfo	1.15	0.1	7724	55
dostarlimab colon cancer	1.47	0.8	4439	58
dostarlimab chpl	1.71	0.8	5807	87

Dostarlimab - Wikipedia
wikipedia.org:443

https://en.wikipedia.org:443/wiki/Dostarlimab

WEBDostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

DA: 15 PA: 83 MOZ Rank: 18

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
nejm.org:443

https://www.nejm.org:443/doi/full/10.1056/NEJMoa2216334

WEBMar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic effects in the treatment of...

DA: 34 PA: 62 MOZ Rank: 92

Dostarlimab Uses, Side Effects & Warnings - Drugs.com
drugs.com:443

https://www.drugs.com:443/mtm/dostarlimab.html

WEBJun 21, 2022 · Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed by surgery. Your doctor will make sure you have the correct tumor type to be treated with dostarlimab.

DA: 40 PA: 69 MOZ Rank: 1

FDA grants accelerated approval to dostarlimab-gxly for dMMR …
fda.gov:443

https://www.fda.gov:443/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-solid-tumors

WEBJul 18, 2023 · On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR)...

DA: 67 PA: 7 MOZ Rank: 49

Dostarlimab: A Review - PubMed
nih.gov:443

https://pubmed.ncbi.nlm.nih.gov:443/35892341/

WEBJul 26, 2022 · Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono- and combination therapies. Keywords: anti-PD-1 antibody; clinical trials; dostarlimab; immunotherapy.

DA: 65 PA: 20 MOZ Rank: 44

Dostarlimab: A Review - PMC - National Center for Biotechnology …
nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC9331682/

WEBJul 26, 2022 · Dostarlimab (also referred to as TSR-042 or Jemperli, commercial name) is a humanized mAb of the IgG4 isotype, produced by recombinant DNA technology in mammalian Chinese hamster ovary (CHO) cells that binds PD-1 on T cells and blocks interactions with its ligands PD-L1 and PD-L2, activating immune responses.

DA: 72 PA: 79 MOZ Rank: 35

Dostarlimab as a Miracle Drug: Rising Hope against Cancer …
nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC9406030/

WEBAug 8, 2022 · In the era of rapid development, dostarlimab, an anti-programmed cell death protein (PD-1) monoclonal antibody has mesmerized the medical profession by showing complete (100%) cure of patients with colorectal cancer. Not only this, the results obtained from clinical trials revealed no major side effects in any of the participants in the …

DA: 65 PA: 46 MOZ Rank: 2

FDA approves dostarlimab-gxly with chemotherapy for …
fda.gov:443

https://www.fda.gov:443/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer

WEBOn July 31, 2023, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for...

DA: 13 PA: 34 MOZ Rank: 73

Dostarlimab-gxly - NCI - National Cancer Institute
cancer.gov:443

https://www.cancer.gov:443/about-cancer/treatment/drugs/dostarlimab-gxly

WEB(dos-TAR-lih-mab) Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of immune cells called T cells. It works by keeping cancer cells from suppressing the immune system.

DA: 70 PA: 96 MOZ Rank: 57

Dostarlimab: A breakthrough in the field of oncology - PMC
nih.gov:443

https://www.ncbi.nlm.nih.gov:443/pmc/articles/PMC9422050/

WEBJul 5, 2022 · Dostarlimab is a new drug previously used to treat endometrial cancers and has a mechanism of action that is in accordance with other PD-1/PD-L1 inhibitors. A recent clinical trial has found Dostarlimab to cure 100% of the CRC patients who were given this drug while also showing no adverse events of grade 3 or higher in any patient.

DA: 86 PA: 76 MOZ Rank: 5